This results in the buildup of appropriate osmolytes like proline, glycine betaine (GB), polyamines, sugars (trehalose, polyols), polyhydric alcohols, and dehydrins
As detailed below, an estimated 3.8 million beneficiaries could be eligible for Bridge as of 2023, based on meeting all the eligibility criteria
The phase 2 BELIEVE trial of bimagrumab plus semaglutide versus bimagrumab monotherapy may have the answer
Of course, there's still work to be done yet: a phase 3 clinical trial is on the way, which will involve a much bigger group of participants over a longer time period
Doctors often use it to treat people with diabetes-related nerve pain and anemia